LB Pharmaceuticals Inc (LBRX)
NGM – Real Time Price. Currency in USD
31.13
-1.56 (-4.79%)
At close: May 12, 2026, 4:00 PM EDT
30.97
-0.16 (-0.51%)
After-hours: May 12, 2026, 7:20 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
31.13
-1.56 (-4.79%)
At close: May 12, 2026, 4:00 PM EDT
30.97
-0.16 (-0.51%)
After-hours: May 12, 2026, 7:20 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $250.2M significantly exceed its total debt $3.6M, ensuring strong financial flexibility
Total current assets $308.4M exceed Total current liabilities $7.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$18.1M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 41.44 | 6.05 | 10 | |
| Quick ratio | 41.44 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 9.0 | |
| Debt to Assets | 0.01 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -2K | -4K | -91K | -321K | -174K |
| Operating Income | -3M | -11M | -65M | -30M | -62M |
| Net Income | -14M | -6M | -63M | -25M | -57M |
| EBITDA | -3M | -11M | -65M | -30M | -62M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | N/A | 1.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | -22.52 | 1.0 |
| Next year | N/A | -16.77 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -222.6 | 26.23 | N/A | 5.5 |
| Y/Y | 999 | 28.98 | N/A | -88.59 | 5.5 |
| 3y average | 999 | -263.08 | N/A | -217.93 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 3.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |